A drug aimed at improving the lives of patients living with Parkinson’s disease will go to the next phase of clinical trials, thanks to a $13.5 million investment raised by Nashville’s Appello Pharmaceuticals. 

Brian Landen

Brian Laden

The clinical-stage pharmaceutical company that focuses on nervous system disorders announced Tuesday that its lead drug, AP-472, will advance to Phase 1b clinical trials.